Oncolytics Biotech Inc ONCY

fda grants priority review to roche

[itntdf]

• Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2

• Additional analyses of INAVO120 will be presented in an oral abstract session at the 2024 American Society of Clinical Oncology Annual Meeting

• The target action date for the FDA decision is 27 November, 2024

[pelaboost]

@itntdf. Thank you. Very Interesting. Also very interesting, Noteable's post on tolerance. Cheers